Resources

NCIMB, the Aberdeen-based microbiology company is delighted to welcome Martin Gouldstone as chairman of the board. Martin brings a wealth of commercial and leadership expertise from drug discovery and contract research.

ELRIG announced the keynote speakers for Cell and Gene Therapy 2026 - Drs Stephen Ward (Cell and Gene Therapy Catapult) and Annarita Miccio (Imagine Institute).

The British Business Bank has made a £50 million cornerstone commitment to Epidarex Capital’s next fund.

Brainomix has been selected by Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD).

Coulter Partners successfully completed a search assignment for mOm Incubators and to place Daniel Green as Chief Operating Officer.

PIR International recently partnered with Slingshot Therapeutics in appointing Bobby Soni as Chief Business Officer.

AAVantgarde Bio, a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), has announced the completion of enrollment in LUCE-1.

An acknowledgment from Astrea Bioseparations celebrating LIB Therapeutics' achievement of FDA approval for LEROCHOL™, including some collaboration efforts.

Coulter Partners successfully led a search assignment for Trevi Therapeutics, placing David Hastings as Chief Financial Officer (CFO).

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 million seed funding round.

Amici Procurement Solutions Rebrands as MyAmici. The rebrand reflects the organization’s strategic evolution from a procurement-focused provider to a comprehensive, end-to-end LabOps platform supporting biotech, medtech, and life-science organisations across every stage of growth.

Complement Therapeutics is one of the leading new gene therapy companies entering into clinical trials. Based on research from the University of Manchester, the company's lead candidate CTx001 is a novel adeno-associated virus (AAV)-based gene therapy targeting an advanced form of dry AMD that leads to irreversible vision loss, with limited therapeutic options. With strong funding and an experienced management team, Complement has made rapid progress and this Fast Track designation comes after IND clearance in December.

Pioneer Group, a specialist in life science infrastructure and venture building, and global biopharmaceutical company AbbVie, have crowned Alceus Bio the winner of their 2025 Golden Ticket programme.

NRG Therapeutics Ltd has announced that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s.

Engitix announced the closing of a $25 million Series A extension financing, by Netherton Investments, a fund investing on behalf of Mike Platt.

EnteroBiotix Limited announced positive final results from for EBX-102-02, a therapeutic for irritable bowel syndrome with constipation and diarrhoea.

Relation and healthcare investment firm Deerfield Management, a current investor,  has launched a new research collaboration to advance therapeutic discovery projects for diseases of high unmet need.

Coulter Partners completed a search assignment for Alethio Therapeutics, placing Dr. Rohit Batta as Chief Executive Officer.

Ikarovec Ltd and VectorBuilder entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used with Ikarovec’s gene therapy candidate IKAR-003.

Dark Blue Therapeutics, a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen.